Sentences with phrase «on drug price increases»

The firm also provided updates on its drug price increases — an issue that CEO Brent Saunders, who has pledged to limit branded price hikes to the single digits, has turned into a pet project.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

Not exact matches

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

By contrast, while the cost of older, branded pharmaceuticals continue to rise and contribute to increased spending, when discounting is considered, prices of these drugs increased, on average, 2.8 % in 2015, the lowest growth rate in years.

While we wait to see how much Newfoundland is able to extract, note that Ottawa offered two other similarly vague compensation deals to get CETA through: One on drug prices, tied to a lengthening of patent protection, and another to the dairy industry as protection against an increase in duty - free European cheese.

But before his arrest, he said he'd use KaloBios as a vehicle to nab another niche drug, this time for treatment of the parasitic infection Chagas disease, and dramatically increase its price to the $ 60,000 to $ 100,000 range after helping it win FDA approval (the drug is approved in other countries and is provided to patients in the U.S. on a special and selective basis).

But at the same time drug companies were increasing prices for many drugs, insurance plans have been going through their own transformation, leaving more families like the LePeres on the hook for far more of that cost.

Both companies have since rolled back their price increases, and experts say that while drug prices will continue to rise the practice of hiking prices purely for profit may be on the wane.

Before, during, and after the trial, Shkreli has cultivated a reputation as America's most hated man, increasing the price of a life - saving drug by 5,000 %, holding an anticipated Wu - Tang album hostage, harassing women on Twitter, and for his smug court appearances.

She apparently declined, saying she wasn't bothered much by the price increase because her insurance plan covered the drug anyway, according to the version of events that Valeant posted on its website Tuesday.

Often it turns out that the price increases by Valeant and Turing that have provoked the most criticism have been on drugs that are off - patent — meaning generic competitors are free to enter the market, typically bringing the price that most people pay for the drugs way down.

The poster boy for prescription drug price increases was arrested on securities fraud charges this week.

Wednesday's hearing will be primarily focused on Valeant's drastic price increases for two of its heart drugs.

Novartis (nvs) chief Joe Jiminez has been touting a pricing model that incorporates drugs» real - world outcomes for years, stressing the importance of placing patients before profits; Regeneron (regn) head honcho Len Schliefer had some tough words for fellow panelists from Eli Lilly (lly) and Pfizer (pfe)(who argued that media reports about their own continued reliance on price increases to drive revenues is misleading) during Forbes» event.

While the drug maker has responded to the massive backlash over its extravagant price increase on the device by boosting its patient assistance programs and introducing an authorized generic EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Allergan chief Brent Saunders and Danish diabetes giant Novo Nordisk have both already volunteered to limit their price increases on drugs to less than 10 % (note: a 9 % price hike on a drug is still pretty high relative to inflation).

In fact, when pressed on the issue, Verheul speculated that perhaps costs would not increase since Canadians already pays higher prices for pharmaceutical drugs than consumers in European countries such as the UK, France or Germany.

Entrepreneurs noticing the great profits to be made in the marijuana market would start their own grow operations, increasing the supply of marijuana on the street, which would cause the street price of the drug to fall to a level much closer to the cost of production.

But you probably know Mr. Shkreli from his company Turing Pharmaceuticals's outrageous increasing of prices on a drug that helps people with compromised immune systems fight parasitic infections.

The charges suggest that a small group of health - care firms — ones that acquire the rights to drugs and significantly increase their prices — is drawing the scrutiny of regulators and prosecutors, with a possible chilling effect on aggressive drug - pricing strategies.

Biotech stocks slumped Tuesday ahead of the Democratic presidential debate on speculation that candidates will call for measures to limit drug - price increases.

While most of the attention on pharmaceutical prices has been on new drugs for diseases like cancer, hepatitis C and high cholesterol, there is also growing concern about huge price increases on older drugs, some of them generic, that have long been mainstays of treatment.

** A message from the Coalition for Affordable Prescription Drugs (CAPD): Prescription drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on Drugs (CAPD): Prescription drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on drugs are often critically important to seniors» health, and yet drug companies continue to increase prices for the very drugs they rely on drugs they rely on most.

The market selloff in biotech began last year when Hilary Clinton commented on drug price gouging and the need for increased regulation.

Trump's long - awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of «getting away with murder» and instead focus on increasing private competition and requiring more openness about costs.

If they can afford the «War on drugs» just by increasing price, they can react in the same way to this change.

Prices for some generic drugs have increased in recent years, adversely affecting patients who rely on them.

These include patent expirations, the rise of competition from generics, a downward pressure on drug prices, increasing scrutiny from regulators and health technology assessment bodies, pressure to move research offshore, and the crisis in R&D productivity.

Skyrocketing drugs prices are increasing pressure on an already troubled NHS and becoming a barrier to bringing new therapies to patients.

Some politicians have called for: Congressional hearings on the escalating pricing, an investigation by the Federal Trade Commission, and action by the U.S. Food and Drug Administration to increase competition by hastening approvals of competitors» products, the AP reported.

The drug tamoxifen, for instance, helps many women with breast cancer, but they pay the price of an increased risk of endometrial cancer.1 Medicine would do much better concentrating on genuine prevention — especially through nutrition.

Seniors started getting a 50 % price break on some prescription drugs not covered by Medicare, with additional savings increasing over time.